Daniel Radin

Image: DanDaniel Radin  

Education:

B.S. University of Rochester (2017)

Current Position:

5th Year MSTP

3rd Year Grad Student

Advisor:

Stella Tsirka, PhD

Graduate Program:

Molecular & Cellular Pharmacology

Research Interest:

High grade-gliomas, including the universally lethal grade 4 glioblastoma, foster a very complex tumor microenvironment marked by its strikingly immunosuppressive nature. This allows gliomas to evade eradication by the host’s intrinsic immune defenses. Notably, up to a third of cells in a glioma biopsy are comprised of innate immune cells such as macrophages and microglia, CNS resident macrophages. Once entrapped in the tumor microenvironment, these innate immune cells are subverted to support tumor cell proliferation, angiogenesis and hinder the anti-cancer activities of the immune system. My research focuses on methods by which we can ‘re-educate’ these innate immune cells to exert pro-inflammatory, tumor rejecting qualities to curb the growth of these intractable neoplasias.

Publications:

Dai, K, Radin, D., Leonardi D. (2019). PINK1 depletion sensitizes non-small cell lung cancer to glycolytic inhibitor 3-bromopyruvate: involvement of ROS and mitophagy. Pharmacological reports. 71(6): 1184-1189.

Kumar, V, Radin, D., Leonardi D. (2019). Studies examining the synergy between Dihydrotanshinone and Temozolomide against MGMT+ glioblastoma cells in vitro: predicting interactions with the blood-brain barrier. Biomedicine and Pharmacotherapy. 109: 386-390.

Radin, D., Li, Y., Rogers, G., Purcell, R., Lippa, A. (2018). Tarps differentially affect the pharmacology of ampakines. Biochemical pharmacology. 154: 446-451.

Johnson, S., Radin, D., Purcell. R., Lippa A. (2018). Effects of chronic systemic low- impact ampakine treatment on neurotrophin expression in rat brain. Biomedicine and pharmacotherapy. 105: 540-544.

Radin, D., Rogers, G., Hewitt, K., Purcell R., Lippa, A. (2018). Ampakines attenuate staurosporine-induced cell death in primary cortical Neurons: Implications in the ‘chemo-brain’ phenomenon. Anticancer research. 38(6):3461-3465.

Radin, D., Li, Y., Rogers, G., Purcell, R., Lippa, A. (2018). Stargazin differentially modulates ampakine gating kinetics and pharmacology. Biochemical pharmacology. 148: 308-314.

Radin, D., Krebs, A,. Maqsudlu, A., Patel, P. (2017). Our ACE in the hole: Justifying the use of angiotensin-converting enzyme inhibitors as an adjuvant to standard chemotherapy. Anticancer Research. 38(1): 45-49.

Radin, D., Purcell. R., Lippa. A. (2017). Oncolytic properties of ampakines in vitro. Anticancer Research. 38(1): 265-269.

Purcell, R., Lynch, G., Gall, C… Radin, D., Lippa, A. (2017). Brain vacuolation resulting from administration of the type II ampakine CX717 is an artifact related to molecular structure and chemical reaction with tissue fixative agents. Toxicol Sci. 162(2):383-395.

Kumar, V., Radin, D., Leonardi, D. (2017). Probing the oncolytic and chemosensitizing effects of dihydrotanshinone in an in vitro glioblastoma model. Anticancer Research. 37: 6025-30.

Kim, D., Radin, D., Leonardi, D. (2017). Probing the molecular mechanisms governing the oncolytic activity of Paeonia suffruticosa on triple-negative breast cancer cells in vitro. Anticancer Research. 37(9). 4813-4819.

Radin, D., Patel, P. (2017). BDNF: an oncogene or tumor suppressor?. Anticancer Research. 37(8). 3983-3990.

Radin, D., Patel, P. (2017). A current perspective on the oncopreventive and oncolytic properties of selective serotonin reuptake inhibitors. Biomed and Pharmcother. 87. 636-639.

Radin, D., Zhong, S., Purcell, R, Lippa, A. (2016). Acute ampakine treatment ameliorates age-related deficits in long-term potentiation. Biomed and Pharmacother. 6(84). 806-809.

Radin, D., Patel. P. (2016). Delineating the molecular mechanisms of Tamoxifen’s oncolytic activity in estrogen receptor-negative cancers. European Journal of Pharmacology. 781. 173-180.

Radin, D., Lippa, A., Patel, P., Leonardi, D. (2015). Lifeguard inhibition of Fas-mediated apoptosis: A possible mechanism for explaining the cisplatin resistance of triple-negative breast cancer cells. Biomed and Pharmacother. 77. 161-166.

Patel, P., Radin, D., Leonardi, D. (2014). High Dose Estrogen Therapy: A Novel Mechanism of Action in Treating Estrogen Receptor-Negative Breast Cancers. Int. J. Sci. Eng. Res. 5(8). 289-295.

Zhou, L., Radin, D., Patel, P., Leonardi, D. (2014). The double life of hTERT: Identification of a novel function and an explanation of mechanism. Int. J. Sci. Eng. Res., 5(6), 643-647.